How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Drugs for Type 2 Diabetes – Project Protocol

of interest outlined in Table 3. Interventions of interest, including fixed-dose combinations and mixed insulin products are further detailed in Tables 1 and 2. Detailed eligibility criteria for studies are provided in Table 4. Studies will not be excluded based on outcomes reported. Weight-loss drugs (e.g., orlistat, sibutramine) included in previous CADTH reviews will not be included in this update. The primary role of such drugs is to lower body weight rather than to treat hyperglycemia. Table 3

2016 CADTH - Therapeutic Review

64. Drugs That May Cause or Exacerbate Heart Failure Full Text available with Trip Pro

suppressants x Major A Valvular damage Intermediate Fenfluramine, dexfenfluramine, and sibutramine have been removed from the US market Bipolar medications Lithium x Major C Direct myofibrillar degeneration, adrenergic stimulation, calcium ion influx interference Intermediate to delayed Reversible on discontinuation Ophthalmological medications Topical β-blockers x Major C Negative inotrope Immediate to intermediate Consider lowering the dose or discontinuing; reversible on discontinuation Topical

2016 American Heart Association

65. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

committee cautions against the use of ephedra, sibutramine, and other weight-loss prepara- tions because they may contribute to the development of HF and should be avoided. 8 Currently, given the above concerns and the lack of evidence on intentional weight loss in HF, the 2009 AHA scientific statement on promoting self-care in individu- als with HF suggests weight loss only if the BMI is >40 kg/m 2 . 249 If the BMI is 35 kg/m 2 , gastrointestinal surgery may be an option. Additionally, in patients (...) or physical activity for the pur- poses of improving health-related QOL or managing comorbidities such as diabetes mellitus, hypertension, or sleep apnea may be reasonable in obese patients with HF (Class IIb; Level of Evidence C). 2. Sibutramine or ephedra weight loss prepara- tions are contraindicated in HF . Use of ephedra weight-loss preparations may contribute to the development of HF and should be avoided (Class III: Harm; Level of Evidence C). No Data Weight reduction, including with bariatric

2016 American Heart Association

66. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

; RR = rel- ative risk; RYGB = Roux-en-Y gastric bypass; SAD = sagittal abdominal diameter; SBP = systolic blood pres- sure; SCOUT = Sibutramine Cardiovascular Outcome Trial; SG = sleeve gastrectomy; SHBG = sex hormone- binding globulin; SIEDY = Structured Interview on Erectile Dysfunction; SNRI = serotonin-norepinephrine reuptake inhibitors; SOS = Swedish Obese Subjects; SS = surveillance study; SSRI = selective serotonin reuptake inhibitors; STORM = Sibutramine Trial on Obesity Reduction

2016 American Association of Clinical Endocrinologists

67. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

Apr 13]. Available from: National Heart, Lung, and Blood Institute. Aim for a healthy weight: key recommendations [Internet]. Bethesda (MD): The Institute; [2014]. [cited 2015 Apr 13]. Available from: Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009 Sep;10(5):564-75. Bray GA. Medications for weight reduction. Med Clin North Am. 2011 Sep;95(5):989-1008

2015 CADTH - Issues in Emerging Health Technologies

68. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

Apr 13]. Available from: National Heart, Lung, and Blood Institute. Aim for a healthy weight: key recommendations [Internet]. Bethesda (MD): The Institute; [2014]. [cited 2015 Apr 13]. Available from: Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009 Sep;10(5):564-75. Bray GA. Medications for weight reduction. Med Clin North Am. 2011 Sep;95(5):989-1008

2015 CADTH - Issues in Emerging Health Technologies

71. Antidepressants for polycystic ovary syndrome. (Abstract)

potential sources of bias.We found no studies reporting any of our primary review outcomes (depression and allied mood disorder scores, quality of life and adverse events). Only one study with 16 women was eligible for inclusion. This study compared sibutramine versus fluoxetine in women with PCOS, and reported only endocrine and metabolic outcomes. It was unclear whether the participants had psychological problems at baseline. No significant difference was found between the groups for any

2013 Cochrane

72. Obesity: European patients protected against lorcaserin, a psychotropic drug sold as an appetite suppressant

) Benfluorex: the appetite- suppressant amphetamine is finally suspended from sale in France (November 2009) Sibutramine: withdrawn from the European market at last! (July 2010) Obesity: diet, physical exercise and support are the priorities (April 2009) Rimonabant: marketing authorisation suspended... at last! Prescrire Int 2009; 18 (100) : 61. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously Prescrire Your message has been sent

2014 Prescrire

74. BMI Reduction and Chronic Disease Management

from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012 Jun;14(6):523-30. PubMed: PM22192338 20. Shea MK, Nicklas BJ, Houston DK, Miller ME, Davis CC, Kitzman DW, et al. The effect of intentional weight loss on all-cause mortality in older adults: results of a randomized BMI Reduction for Chronic Disease Management 4 controlled weight-loss trial. Am J Clin Nutr [Internet]. 2011 Sep [cited 2014 Apr 16];94(3):839-46. Available from: http://www.ncbi.nlm.nih.gov/pmc

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

75. Obesity and reproduction: a committee opinion

blocker, was accompanied by suicidal ideation and behavioral changes. Sibutramine, a serotonin- norepinephrine reuptake inhibitor, was linked to myocardial infarction and stroke (138). BariatricSurgery In 2011, over 340,000 bariatric surgical procedures were performedworldwide,withtheUnitedStates/Canadaperform- ing the largest number of operations (over 100,000 cases) (149).Commonbariatricsurgicalproceduresareeitherrestric- tive (i.e., sleeve gastrectomy [SG], laparoscopic adjustable gastric band

2015 Society for Assisted Reproductive Technology

77. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies Full Text available with Trip Pro

Organisation) diet, have greater weight loss and lower attrition rates in the short term, but longer-term evidence is lacking. Weight-loss medications available to date have been disappointing because of the lack of sustained weight loss and the risk of side effects. Several weight-loss medications have been withdrawn from market due to harmful effects, the most recent being sibutramine. In addition, weight loss achieved using medication is unlikely to have the same health benefits as weight loss achieved (...) . Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev 2009; 10: 36-50. Therapeutic Goods Administration. Sibutramine (Reductil) – withdrawal in Australia. 8 Oct 2010. (accessed Feb 2013). National Health and Medical Research Council. Clinical practice guideline for the management of overweight and obesity in adults, adolescents and children in Australia. Public consultation draft — 29 March 2012

2013 MJA Clinical Guidelines

78. Alogliptin and alogliptin/pioglitazone

or substance abuse within the 2 years prior to Screening. • Subject has an active proliferative retinopathy. • Subject has been using medicine for weight loss within one month prior to screening (such as Xenical, Sibutramine, Phenylpropanolamine or similar nonprescription drugs). • Subject has a history of organ transplantation. • The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g

2012 FDA - Drug Approval Package

79. Idebenone Treatment of Early Parkinson's Diseasesymptoms

) Exclusion Criteria: (1)Patients with disturbance of consciousness, aphasia and mental illness; patients with major depression (HAD scale score ≥ 15 points) (2)Patients with Parkinson's superimposition syndrome and patients with secondary Parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.) (3)Patients who have long-term use of dopamine blockers (such as potent neuroleptics, sibutramine, reserpine, metoclopramide, etc

2018 Clinical Trials

80. Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

(phentermine, sibutramine, orlistat) or lipid dissolving injections within 3 months. Over 3 days of treatment with oral or parenteral corticosteroids within 2 weeks of the screening visit. Recent history (within 2 years prior to the screening visit) of alcohol or drug abuse. Significant change in smoking habits within 3 months prior to screening. Participated in any clinical study with an investigational drug, biologic, or device within 3 month prior to screening. Significant change in diet or level

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>